The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

post
Cloud and AI in Pharma: Driving Digital Transformation in Pharmaceutical Operations
Read More

post
Biopharma M&A in 2026: Key Trends, Deal Drivers, and Strategic Outlook
Read More

case-study
The Journey Leading to an Approved NDA
Read More

infographic
Early CMC Decisions that Shape IND Readiness
Read More
Let's move from science to success.
Let’s Talk
